The stock of Evgen Pharma PLC (LON:EVG) is a huge mover today! The stock increased 4.90% or GBX 1.2 on November 30, hitting GBX 25.7. About 7,811 shares traded hands. Evgen Pharma PLC (LON:EVG) has risen 24.05% since April 29, 2016 and is uptrending. It has outperformed by 18.82% the S&P500.
The move comes after 6 months positive chart setup for the GBX 18.64M company. It was reported on Nov, 30 by Barchart.com. We have GBX 28.01 PT which if reached, will make LON:EVG worth GBX 1.68M more.
Evgen Pharma PLC (LON:EVG) Ratings Coverage
Out of 2 analysts covering Evgen Pharma Plc (LON:EVG), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Evgen Pharma Plc has been the topic of 20 analyst reports since October 26, 2015 according to StockzIntelligence Inc. Northland Capital maintained the shares of EVG in a report on Thursday, September 15 with “Buy” rating. The stock of Evgen Pharma PLC (LON:EVG) earned “Buy” rating by Northland Capital on Monday, December 7. The rating was maintained by Beaufort Securities on Wednesday, June 1 with “Speculative Buy”. The stock of Evgen Pharma PLC (LON:EVG) earned “Speculative Buy” rating by Beaufort Securities on Thursday, March 3. On Wednesday, December 2 the stock rating was maintained by Northland Capital with “Buy”. The stock of Evgen Pharma PLC (LON:EVG) has “Speculative Buy” rating given on Tuesday, November 24 by Beaufort Securities. The stock of Evgen Pharma PLC (LON:EVG) has “Buy” rating given on Wednesday, March 2 by Northland Capital. As per Tuesday, January 5, the company rating was maintained by Beaufort Securities. Northland Capital maintained the stock with “Buy” rating in Wednesday, January 6 report. Northland Capital maintained it with “Buy” rating and GBX 79 target price in Wednesday, August 17 report.
Another recent and important Evgen Pharma PLC (LON:EVG) news was published by Reuters.com which published an article titled: “BRIEF-Evgen Pharma granted orphan drug designation for stabilised sulforap…” on August 24, 2016.
Evgen Pharma plc is a clinical-stage drug development firm focused on cancer and neurological disease. The company has a market cap of 18.64 million GBP. The Firm operates through the segment of development of pharmaceutical products all within the United Kingdom. It currently has negative earnings. The Company’s pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.